Therapeutic Options for COVID-19 Patients - Minnesota Dept. of Health

Therapeutic Options for COVID-19 Patients

Information about investigational therapeutics to be updated as new information emerges.

Monoclonal Antibody (mAb) Treatment

Monoclonal antibody treatments are available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for non-hospitalized COVID-19 positive people.

Ethical Guidance and Eligibility

Eli Lilly - Bamlanivimab (BAM)

Regneron - Casirivimab and Imdevimab

  • Regeneron: Authorized for FDA Emergency Use only Casirivimab and Imdevimab
    Website of the manufacturer of casirivimab and imdevimab. See additional links, resources, and guidance to facilities administering the treatment, including:
    • FDA letter of authorization
    • Fact sheet for U.S. health care providers
    • Fact sheet for patients and caregivers in English and Spanish
    • Dear Healthcare Provider letter (prescribing information)

Ventilators and Cardiopulmonary Resuscitation

Remdesivir

Remdesivir is available through the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for people with severe COVID-19.

Thank you for your continued partnership. For health care questions, please contact the MDH provider hotline at 651-201-5414.

Updated Wednesday, 25-Nov-2020 07:54:03 CST